Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms, Primary Peritoneal Neoplasm
Conditions
Keywords
advanced solid tumor, Ovarian cancer, Primary peritoneal cancer, Fallopian tube cancer
Brief summary
This is a two-part, Phase 1, open-label, multicenter, dose escalation study of KHK2866 as monotherapy in patients with advanced solid tumors, and in combination with chemotherapy in subjects platinum-sensitive and platinum-resistant ovarian cancer.
Detailed description
During Phase 1a, groups of eligible patients with advanced solid tumors will receive KHK2866 as monotherapy in escalating doses. The Phase 1b portion will enroll patients with ovarian cancer who will receive KHK2866 in combination with one of three chemotherapy regimens (Arms): gemcitabine+carboplatin (platinum-sensitive, weekly paclitaxel (platinum-resistant), or pegylated liposomal doxorubicin (platinum-resistant). Escalating doses of the combination of KHK2866 and the chemotherapy regimen will given to two groups of subjects per Arm. The goal of the study is to learn about the side effects of KHK2866 alone or given in combination with chemotherapy. All subjects will receive study therapy for up to 6 cycles (up to 12 cycles for subjects assigned to PLD \[Arm 3 of Phase 1b\]), or until disease progression, the development of severe side effects, noncompliance or withdrawal of consent by the subject, or other removal criteria whichever comes first.
Interventions
BIOLOGICALKHK2866
Potentially therapeutic monoclonal antibody for the treatment of advanced cancer and ovarian cancer.
Combination chemotherapy with KHK2866 to treat advanced platinum-sensitive ovarian cancer. Gemcitabine dose 1000 mg/m2, Carboplatin dose AUC=4
DRUGpaclitaxel
Combination chemotherapy with KHK2866 to treat advanced platinum-resistant ovarian cancer. Paclitaxel will be administered weekly at a dose of 80 mg/m2.
DRUGpegylated liposomal doxorubicin
Combination chemotherapy with KHK2866 to treat advanced platinum-resistant ovarian cancer. PLD will be administered weekly at a dose of 40 mg/m2.
Sponsors
Kyowa Hakko Kirin Pharma, Inc.
Kyowa Kirin Co., Ltd.
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically or cytologically documented, measurable or non-measurable, advanced primary or recurrent solid tumor (Phase 1a only) which is unresponsive to standard therapy or for which there is no standard therapy available. * Histologically or cytologically documented ovarian, primary peritoneal, or fallopian tube cancer. * The subject has objective radiographic disease progression and either unmeasurable or measurable disease during or following the last treatment regimen, or serum cancer antigen-125 (CA-125) greater than 2X the upper limit of normal (\[ULN\] \>70 U/mL * Life expectancy \>3 months. * Performance status \< 3 at study entry. * Age \> 18 years. * Normal left ventricular ejection fraction. * Recovered from the effects of recent surgery, radiotherapy, chemotherapy, hormonal therapy, or other therapies for cancer * Preserved hepatic, renal, and hematopoetic organ function. * Male and female subjects must use medically accepted contraception.
Exclusion criteria
* Ovarian malignancy of low malignant potential. * Received anti-cancer chemotherapy, hormonal therapy, radiotherapy, immunotherapy, or investigational agents within 4 weeks prior to the first dose of KHK2866 (6 weeks for nitrosourea or mitomycin chemotherapy). * received Mabs or had major surgery within 4 weeks of the first dose of KHK2866. * Requires administration of a prohibited medication or treatment including: prophylactic use of erythroid and/or granulocyte colony stimulating factors; concurrent anti-cancer treatment; biologic response modifiers for any condition * Brain metastases, leptomeningeal or primary brain neoplasm, even if treated. * Previously untreated or uncontrolled epidural metastasis * Cerebrovascular accident, Transient ischemic attack; symptomatic head trauma, or seizures or any kind within 6 months * Dementia, or other disorders of mentation or difficulty speaking or difficulty with comprehension. * Suspected impending bowel obstruction * The subject is pregnant,or is lactating. * Significant uncontrolled intercurrent illness * Known HIV infection or AIDS-related illness. * Known active hepatitis B or C or other active liver disease. * Psychiatric illness, disability or social situation that would compromise the subject's safety, ability to provide consent, or limit his/her compliance with study requirements. * Experienced a unmanageable hypersensitivity reactions to Mabs or other therapeutic proteins. * History of second primary cancer, with the exception of: a) curatively resected non-melanomatous skin cancer; b) curatively treated cervical carcinoma in-situ; or c) other primary solid tumor treated with curative intent and no known active disease present and no treatment administered during the last 2 years. * Additional
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants with Adverse Events as a Measure of Safety and Tolerability | at least 60 days, and up to 6 months | The safety of KHK2866 will be determined by reported adverse events (AEs), changes in physical examinations, vital sign measurements, electrocardiograms (ECGs), clinical laboratory evaluations, and treatment discontinuation due to toxicity. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| To determine the Cmax, Tmax, AUC and half life of KHK2866 when administered i.v. as monotherapy | at least 28 days and up to 6 months | Participants will have serial blood samples taken to determine the PK profile of the study drug. |
| To evaluate the changes in serum HB-EGf in participants administered KHK2866 | at least 60 days, and up to 6 months | Participants will have serial blood samples taken to develop the PD profile. |
| To screen for the development of antibodies against KHK2866 (immunogenicity). | at least 60 days and up to 6 months | Participants will have serial blood samples to check for the development of anti-KHK2866 antibodies. |
| To describe any anti-tumor activity observed when KHK2866 is administered i.v. as monotherapy, or in combination with chemotherapy. | at least 60 days and up to 6 months | — |
Countries
United States
Outcome results
None listed